Production (Stage)
E
GlycoMimetics, Inc. GLYC
$0.1766 -$0.0172-8.88% NASDAQ
Recommendation
Prev Close
$0.1938
Volume
2,994,916
Avg Vol (90D)
2,054,808
Market Cap
$12.51M
Dividend & Yield
--
52-Week Range
$0.1406 - $0.63
P/E (TTM)
--
EPS (TTM)
-$0.4573
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
What Does the Market Think About GlycoMimetics?
6/6/2025 - Benzinga
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
6/5/2025 - GuruFocus
GlycoMimetics (GLYC) Stockholders Approve Merger with Crescent Biopharma GLYC Stock News
6/5/2025 - GuruFocus
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related ...
6/5/2025 - GuruFocus
GlycoMimetics stockholders approve proposed Crescent Biopharma merger
6/5/2025 - The Fly
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
6/5/2025 - Business Wire
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
5/29/2025 - Globe Newswire
GlycoMimetics (NASDAQ:GLYC) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened
5/28/2025 - Ticker Report
GlycoMimetics (NASDAQ:GLYC) Research Coverage Started at StockNews.com
5/20/2025 - Ticker Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders
5/18/2025 - Globe Newswire
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & ...
5/16/2025 - GuruFocus
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
5/16/2025 - Business Wire
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC)
5/12/2025 - Ticker Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, FARO, AVDX, GLYC on Behalf of Shareholders
5/9/2025 - Globe Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - GLYC, BRZH, PRA, FVNNU
5/7/2025 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COLB, PRA, GLYC on Behalf of Shareholders
5/7/2025 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger GLYC, BRZH, PRA, FVNNU
5/6/2025 - Globe Newswire
Crescent Biopharma Appoints David Lubner to Board of Directors
4/28/2025 - Globe Newswire
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com
4/9/2025 - Ticker Report
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
4/3/2025 - Globe Newswire
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC)
3/25/2025 - Ticker Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
3/5/2025 - PR Newswire
GlycoMimetics (NASDAQ:GLYC) Research Coverage Started at StockNews.com
2/21/2025 - Ticker Report
GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com
2/2/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$23.76M
EBIT (TTM)
-$23.79M
Net Income (TTM)
-$29.49M
Balance Sheet
Total Assets (Q)
$5.99M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$2.62M
Book Value Per Share (Q)
$0.0523
Cash Flow
Cash from Operations (TTM)
-$25.70M
Cash from Investing (TTM)
$27.50K
Cash from Financing (TTM)
$500.00
Net Change in Cash (TTM)
-$25.67M
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
-0.41
7-Day Total Return
-17.17%
30-Day Total Return
-32.34%
60-Day Total Return
-31.97%
90-Day Total Return
-30.09%
Year to Date Total Return
-30.83%
1-Year Total Return
-31.39%
2-Year Total Return
-90.66%
3-Year Total Return
-71.52%
5-Year Total Return
-94.48%
52-week Low
Oct 09, 2024 - $0.1406
52-week High
Oct 29, 2024 - $0.63
Valuation
Market Cap
$12.51M - Nano Cap
Enterprise Value
$6.89M
Price/Sales (TTM)
--
Price/Book (Q)
3.71
Dividends and Shares
Shares Outstanding
64.52M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.glycomimetics.com
Phone Number
240 243 1201
Address
P.O. Box 65
Monrovia, MD 21770
Country
United States
Year Founded
2003
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia... more
NASDAQ 06/09/2025 4:00PM Eastern Quotes delayed